Stock IDP BIOGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Biogen Inc. Xetra

Equities

IDP

US09062X1037

Market Closed - Xetra
Other stock markets
 11:35:33 2024-05-15 EDT 		After market 16:00:00
214.8 EUR +4.27% Intraday chart for Biogen Inc. 216.3 +0.70%
09:53pm Sector Update: Health Care Stocks Advance Late Wednesday Afternoon MT
07:53pm Sector Update: Health Care Stocks Advance in Afternoon Trading MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Advance Late Wednesday Afternoon
MT
Sector Update: Health Care Stocks Advance in Afternoon Trading
MT
Sector Update: Health Care
MT
Argus Raises Biogen's Price Target to $250 From $240
MT
Equity Markets Rise Intraday as Consumer Inflation Cools
MT
S&P 500, Nasdaq Composite Touch Record Highs After Consumer Price Index Eases
MT
Easing Inflation Spurs S&P 500, Nasdaq Composite to Record Highs
MT
Biogen Partner Eisai Submits FDA Biologics Application for Early Alzheimer's Self-Injection Drug
MT
Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
RE
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
GL
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
PR
Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
RE
MOVES -Lazard hires veteran healthcare dealmaker Colocci as vice chairman
RE
Redburn Atlantic Adjusts Price Target on Biogen to $235 From $275, Keeps Neutral Rating
MT
FDA Sets June 10 Advisory Panel Meeting on Eli Lilly Alzheimer's Drug
DJ
People with two copies of a risk gene have genetic form of Alzheimer's, scientists say
RE
HSBC Adjusts Price Target on Biogen to $342 From $339, Maintains Buy Rating
MT
Biogen Reports Progress on Corporate Responsibility Priorities
AQ
Wall Street: buoyed by Tesla, confident ahead of FOMC meeting
CF
Wall Street: buoyed by Tesla, confident ahead of FOMC meeting
CF
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIIB Stock
  4. IDP Stock
  5. News Biogen Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW